Yeah I think both of you (Babba, The buck) have valid points.
Par are throttling back on expenses and are definitely heavily focused on the FDA and TGA pathways going forward. There is now nothing more important. There is small scope for limited exposure via such conferences as OARSI but even that's being cut right back with absolute minimum staff attending.
It's definitely worth some exposure as these are the conferences where word of what we have can spread. I'm very much looking forward to hearing first hand how Par present the exciting 008 data amongst peers and how its recieved and trying to gauge the reactions, sence of potential and feedback.
General OA media and info, page-646
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.5¢ | 22.0¢ | $65.40K | 290.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 96390 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |